Chang Shih C, Huq Redwan, Chhabra Sandeep, Beeton Christine, Pennington Michael W, Smith Brian J, Norton Raymond S
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Vic., Australia.
Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, USA.
FEBS J. 2015 Jun;282(12):2247-59. doi: 10.1111/febs.13294. Epub 2015 Apr 23.
The voltage-gated potassium channel Kv1.3 is an important target for the treatment of autoimmune diseases and asthma. Blockade of Kv1.3 by the sea anemone peptide K⁺-channel toxin from Stichodactyla helianthus (ShK) inhibits the proliferation of effector memory T lymphocytes and ameliorates autoimmune diseases in animal models. However, the lack of selectivity of ShK for Kv1.3 over the Kv1.1 subtype has driven a search for Kv1.3-selective analogues. In the present study, we describe N-terminally extended analogues of ShK that contain a negatively-charged Glu, designed to mimic the phosphonate adduct in earlier Kv1.3-selective analogues, and consist entirely of common protein amino acids. Molecular dynamics simulations indicated that a Trp residue at position [-3] of the tetrapeptide extension could form stable interactions with Pro377 of Kv1.3 and best discriminates between Kv1.3 and Kv1.1. This led to the development of ShK with an N-terminal Glu-Trp-Ser-Ser extension ([EWSS]ShK), which inhibits Kv1.3 with an IC₅₀ of 34 pm and is 158-fold selective for Kv1.3 over Kv1.1. In addition, [EWSS]ShK is more than 2900-fold more selective for Kv1.3 over Kv1.2 and KCa3.1 channels. As a highly Kv1.3-selective analogue of ShK based entirely on protein amino acids, which can be produced by recombinant expression, this peptide is a valuable addition to the complement of therapeutic candidates for the treatment of autoimmune diseases.
电压门控钾通道Kv1.3是治疗自身免疫性疾病和哮喘的重要靶点。来自太阳海葵(Stichodactyla helianthus)的海葵肽K⁺通道毒素(ShK)对Kv1.3的阻断作用可抑制效应记忆T淋巴细胞的增殖,并改善动物模型中的自身免疫性疾病。然而,ShK对Kv1.3的选择性高于Kv1.1亚型,这促使人们寻找Kv1.3选择性类似物。在本研究中,我们描述了ShK的N端延伸类似物,其含有带负电荷的谷氨酸,旨在模拟早期Kv1.3选择性类似物中的膦酸酯加合物,并且完全由常见的蛋白质氨基酸组成。分子动力学模拟表明,四肽延伸部分[-3]位的色氨酸残基可与Kv1.3的Pro377形成稳定相互作用,并且能最好地区分Kv1.3和Kv1.1。这导致了具有N端谷氨酸-色氨酸-丝氨酸-丝氨酸延伸([EWSS]ShK)的ShK的开发,其对Kv1.3的抑制IC₅₀为34 pM,对Kv1.3的选择性是Kv1.1的158倍。此外,[EWSS]ShK对Kv1.3的选择性比对Kv1.2和KCa3.1通道高2900多倍。作为一种完全基于蛋白质氨基酸的高度Kv1.3选择性ShK类似物,可通过重组表达产生,该肽是治疗自身免疫性疾病候选药物补充中的有价值补充。